Carcinogenicity prediction by in vitro human liver cell gene expression and chemical structure

Cancer is one of the leading causes of mortality in the world while the carcinogenicity prediction remains challenging. In this work, carcinogenicity prediction is researched in two ways, by chemical structures and sub-structures and by gene expression exposed to drugs. Probabilistic support vector machine is used to train model by the gene expression data. The results show that the gene expression gives clues about the carcinogenicity. A comprehensive literature mining for top-ranked microarray probes provided by feature selection showed strong relevance between corresponding genes and cancer. This work illustrated that our method is an effective computational strategy for carcinogenicity prediction and cancer biomarker discovery.

[1]  J. Chang,et al.  Identification of salt-inducible kinase 3 as a novel tumor antigen associated with tumorigenesis of ovarian cancer , 2011, Oncogene.

[2]  Yoshihiro Yamanishi,et al.  Extracting Sets of Chemical Substructures and Protein Domains Governing Drug-Target Interactions , 2011, J. Chem. Inf. Model..

[3]  Urs A. Meyer,et al.  Overview of enzymes of drug metabolism , 1996, Journal of Pharmacokinetics and Biopharmaceutics.

[4]  K. D. Sørensen,et al.  The SNP rs6441224 influences transcriptional activity and prognostically relevant hypermethylation of RARRES1 in prostate cancer , 2012, International journal of cancer.

[5]  C. Gespach,et al.  Deregulated expression of homeobox-containing genes, HOXB6, B8, C8, C9, and Cdx-1, in human colon cancer cell lines. , 2000, Biochemical and biophysical research communications.

[6]  R. Dammann,et al.  Promoter Methylation Status of Ras-Association Domain Family Members in Pheochromocytoma , 2015, Front. Endocrinol..

[7]  Vladimir B Bajic,et al.  In silico toxicology: computational methods for the prediction of chemical toxicity , 2016, Wiley interdisciplinary reviews. Computational molecular science.

[8]  Ting Chen,et al.  Global optimization-based inference of chemogenomic features from drug-target interactions , 2015, Bioinform..

[9]  Benjamin J. Raphael,et al.  Pan-Cancer Network Analysis Identifies Combinations of Rare Somatic Mutations across Pathways and Protein Complexes , 2014, Nature Genetics.

[10]  H. Bonkovsky,et al.  Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration , 2000, American Journal of Gastroenterology.

[11]  J. Ptak,et al.  Somatic mutations of GUCY2F, EPHA3, and NTRK3 in human cancers , 2006, Human mutation.

[12]  Jürgen Bajorath,et al.  Design of chemical space networks using a Tanimoto similarity variant based upon maximum common substructures , 2015, Journal of Computer-Aided Molecular Design.

[13]  Daniel C. Liebler,et al.  Elucidating mechanisms of drug-induced toxicity , 2005, Nature Reviews Drug Discovery.

[14]  Li Shang,et al.  Role of microRNA221 in regulating normal mammary epithelial hierarchy and breast cancer stem-like cells , 2015, Oncotarget.

[15]  Andrey A Toropov,et al.  CORAL software: prediction of carcinogenicity of drugs by means of the Monte Carlo method. , 2014, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[16]  J. Gustafsson,et al.  Gene expression in murine mammary epithelial stem cell-like cells shows similarities to human breast cancer gene expression , 2009, Breast Cancer Research.

[17]  Ian Spence,et al.  Combining machine learning models of in vitro and in vivo bioassays improves rat carcinogenicity prediction , 2018, Regulatory toxicology and pharmacology : RTP.

[18]  Hua Yu,et al.  STATs in cancer inflammation and immunity: a leading role for STAT3 , 2009, Nature Reviews Cancer.

[19]  N. Kaplowitz,et al.  Mechanisms of drug-induced liver injury. , 2013, Clinics in liver disease.

[20]  Jie Li,et al.  SDTNBI: an integrated network and chemoinformatics tool for systematic prediction of drug–target interactions and drug repositioning , 2016, Briefings Bioinform..

[21]  R. Uzzo,et al.  A global profile of gene promoter methylation in treatment-naïve urothelial cancer , 2014, Epigenetics.

[22]  Ö. Türeci,et al.  Humoral immune responses of lung cancer patients against the Transmembrane Phosphatase with TEnsin homology (TPTE). , 2015, Lung cancer.

[23]  T. Sasahira,et al.  NEDD 4 binding protein 2-like 1 promotes cancer cell invasion in oral squamous cell carcinoma , 2016, Virchows Archiv.

[24]  Yu Shyr,et al.  Effects of cancer-associated EPHA3 mutations on lung cancer. , 2012, Journal of the National Cancer Institute.

[25]  D. Amacher,et al.  The discovery and development of proteomic safety biomarkers for the detection of drug-induced liver toxicity. , 2010, Toxicology and applied pharmacology.

[26]  G. Ilia,et al.  Potential carcinogenicity predicted by computational toxicity evaluation of thiophosphate pesticides using QSTR/QSCarciAR model , 2017, Drug and chemical toxicology.

[27]  Lara E Sucheston-Campbell,et al.  Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  C. Dang,et al.  MYC-Induced Cancer Cell Energy Metabolism and Therapeutic Opportunities , 2009, Clinical Cancer Research.

[29]  Alexander E. Kel,et al.  Identification of Differentially Expressed Genes by Meta-Analysis of Microarray Data on Breast Cancer , 2008, Silico Biol..

[30]  Cheng Peng,et al.  Novel naïve Bayes classification models for predicting the carcinogenicity of chemicals. , 2016, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[31]  N. Kosaka,et al.  Exosomal tumor-suppressive microRNAs as novel cancer therapy: "exocure" is another choice for cancer treatment. , 2013, Advanced drug delivery reviews.

[32]  H. Yamada,et al.  Prediction model of potential hepatocarcinogenicity of rat hepatocarcinogens using a large-scale toxicogenomics database. , 2011, Toxicology and applied pharmacology.

[33]  D. Kanduc,et al.  Genome‐wide transcriptional profiling in human squamous cell carcinoma of the skin identifies unique tumor‐associated signatures , 2006, The Journal of dermatology.

[34]  Joseph S. Verducci,et al.  A Modification of the Jaccard–Tanimoto Similarity Index for Diverse Selection of Chemical Compounds Using Binary Strings , 2002, Technometrics.

[35]  M. Urioste,et al.  MAX Mutations Cause Hereditary and Sporadic Pheochromocytoma and Paraganglioma , 2012, Clinical Cancer Research.

[36]  H. Ellinger-Ziegelbauer,et al.  Prediction of a carcinogenic potential of rat hepatocarcinogens using toxicogenomics analysis of short-term in vivo studies. , 2008, Mutation research.

[37]  Darko Butina,et al.  Unsupervised Data Base Clustering Based on Daylight's Fingerprint and Tanimoto Similarity: A Fast and Automated Way To Cluster Small and Large Data Sets , 1999, J. Chem. Inf. Comput. Sci..

[38]  P. Brousset,et al.  RNA editing in acute myeloid leukaemia with normal karyotype , 2016, British journal of haematology.

[39]  C. Wongkham,et al.  Roles and Mechanisms of β-Thymosins in Cell Migration and Cancer Metastasis: An Update , 2013, Cancer investigation.

[40]  K. Pacak,et al.  Opposing effects of HIF1α and HIF2α on chromaffin cell phenotypic features and tumor cell proliferation: Insights from MYC‐associated factor X , 2014, International journal of cancer.

[41]  D A Smith,et al.  Role of reactive metabolites in drug-induced hepatotoxicity. , 2010, Handbook of experimental pharmacology.

[42]  Hua Yu,et al.  Tumour immunology: Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment , 2007, Nature Reviews Immunology.

[43]  M. Tessier-Lavigne,et al.  Defining the Ligand Specificity of the Deleted in Colorectal Cancer (DCC) Receptor , 2014, PloS one.

[44]  I. Bièche,et al.  A tumor suppressor gene on chromosome 1p32-pter controls the amplification of MYC family genes in breast cancer. , 1994, Cancer research.

[45]  Hiroshi Yamada,et al.  Open TG-GATEs: a large-scale toxicogenomics database , 2014, Nucleic Acids Res..

[46]  R. Povinelli,et al.  Novel Uses of In Vitro Data to Develop Quantitative Biological Activity Relationship Models for in Vivo Carcinogenicity Prediction , 2015, Molecular informatics.

[47]  N. Hynes,et al.  Key signalling nodes in mammary gland development and cancer: Myc , 2009, Breast Cancer Research.

[48]  Long Yu,et al.  Identification and characterization of nine novel human small GTPases showing variable expressions in liver cancer tissues. , 2002, Gene expression.

[49]  C. David Page,et al.  Human pluripotent stem cell-derived neural constructs for predicting neural toxicity , 2015, Proceedings of the National Academy of Sciences.

[50]  B. Crosas Deubiquitinating enzyme inhibitors and their potential in cancer therapy. , 2014, Current cancer drug targets.

[51]  Jian Zhao,et al.  CarcinoPred-EL: Novel models for predicting the carcinogenicity of chemicals using molecular fingerprints and ensemble learning methods , 2017, Scientific Reports.

[52]  Peng Chen,et al.  MicroRNA-1254 exerts oncogenic effects by directly targeting RASSF9 in human breast cancer. , 2018, International journal of oncology.

[53]  M. Ellis,et al.  TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer. , 2018, Cancer research.

[54]  M. Gariboldi,et al.  Gene expression analysis reveals a different transcriptomic landscape in female and male breast cancer , 2011, Breast Cancer Research and Treatment.

[55]  Aixia Yan,et al.  Carcinogenicity prediction of noncongeneric chemicals by a support vector machine. , 2013, Chemical research in toxicology.

[56]  Vladimir Poroikov,et al.  ROSC-Pred: web-service for rodent organ-specific carcinogenicity prediction , 2018, Bioinform..

[57]  N. Kaplowitz,et al.  Drug-Induced Liver Disorders , 2001, Drug safety.

[58]  P. Lemotte,et al.  TEM8/ANTXR1 blockade inhibits pathological angiogenesis and potentiates tumoricidal responses against multiple cancer types. , 2012, Cancer cell.

[59]  Zengrui Wu,et al.  In Silico Estimation of Chemical Carcinogenicity with Binary and Ternary Classification Methods , 2015, Molecular informatics.

[60]  Payam Shahi,et al.  microRNA-mediated regulation of the tumor microenvironment , 2013, Cell cycle.

[61]  Jürgen Bajorath,et al.  Erratum to: Design of chemical space networks using a Tanimoto similarity variant based upon maximum common substructures , 2015, Journal of Computer-Aided Molecular Design.

[62]  Corinna Cortes,et al.  Support-Vector Networks , 1995, Machine Learning.

[63]  Bo Yin,et al.  Incremental Learning Based on Probabilistic SVM and SVDD and Its Application to Acoustic Signal Recognition , 2017, 2017 International Conference on Sensing, Diagnostics, Prognostics, and Control (SDPC).

[64]  F. Colland,et al.  Ubiquitin-specific proteases as cancer drug targets. , 2011, Future oncology.

[65]  A. Bode,et al.  USP8 Is a Novel Target for Overcoming Gefitinib Resistance in Lung Cancer , 2013, Clinical Cancer Research.

[66]  M. Cantile,et al.  Homeobox genes and cancer. , 1999, Experimental cell research.

[67]  Dario Strbenac,et al.  Regional activation of the cancer genome by long-range epigenetic remodeling. , 2013, Cancer cell.

[68]  William M. Lee Acute Liver Failure in the United States , 2003, Annals of Internal Medicine.

[69]  Joshua A. Bittker,et al.  The Carcinogenome Project: In-vitro Gene Expression Profiling of Chemical Perturbations to Predict Long-Term Carcinogenicity , 2018, bioRxiv.

[70]  A. Nicolas,et al.  Germline mutation in the RAD51B gene confers predisposition to breast cancer , 2013, BMC Cancer.